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Background: Second-line chemotherapy for advanced non-small 
cell lung cancer (NSCLC) improves survival modestly but new strat-
egies are needed. This trial was designed to evaluate an antivascular 
endothelial growth factor strategy with or without standard chemo-
therapy in previously treated NSCLC.
Methods: Patients with stage IIIB/IV NSCLC with performance status 0 
to 1 progressive after first-line chemotherapy were eligible for randomiza-
tion to pemetrexed, sunitinib, or the combination. Patients were stratified 
by performance status, stage, and sex. Primary objective was 18-week 
progression-free survival (PFS) rate; secondary objectives included 
response, overall survival (OS), and toxicity. Target accrual was 225. The 
study was terminated early because of decreasing accrual rates.
Results: Between April 2008 and September 2011, 130 patients were 
registered and randomized; of this, 125 patients were treated. Baseline 
characteristics in the three arms were well balanced. Toxicity was higher 
in the sunitinib-containing arms. The 18-week PFS rate in the peme-
trexed, sunitinib, and combination arms was 54% (95% confidence 
interval [CI], 40–71), 37% (95% CI, 25–54), and 48% (95% CI, 35–66), 
respectively (p = 0.25). Median PFS in the pemetrexed,  sunitinib, and 
combination arms in months was 4.9 (2.1–8.8), 3.3 (2.3–4.2), and 3.7 
(2.5–5.8), respectively (p = 0.18). There was an overall statistically sig-
nificant difference in OS between the three arms: median OS in months 
was 10.5 (8.3–20.2) for pemetrexed, 8.0 (6.8–13.5) for  sunitinib, and 
6.7 (4.1–10.1) for the combination (p = 0.03).
Conclusion: Pemetrexed had a superior toxicity profile to either suni-
tinib or the combination of pemetrexed and sunitinib. The 18-week 
PFS rate was not significantly different between the arms. OS was 
significantly better with pemetrexed alone compared with the two 
sunitinib-containing arms, with the doublet performing worst for OS.
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(J Thorac Oncol. 2014;9: 214–221)
Antiangiogenic therapy as a therapeutic target in non– small-cell lung cancer (NSCLC) was demonstrated as beneficial 
by Eastern Cooperative Oncology Group 4599, which showed 
that the addition of bevacizumab, a monoclonal antibody to 
vascular endothelial growth factor (VEGF), to standard che-
motherapy improved overall survival (OS) among advanced 
nonsquamous NSCLC patients treated in the first-line set-
ting.1 Multiple other antiangiogenic drugs, including many 
small-molecule tyrosine kinase inhibitors of VEGF receptor 
(VEGFR), have been developed and are in clinical testing 
across a broad range of tumor types.2–4
We hypothesized that the addition of antiangiogenic ther-
apy to standard chemotherapy in the second-line setting could 
lead to improved outcomes. We therefore designed this random-
ized phase 2 trial to treat patients on one of three arms: Arm I, 
pemetrexed alone; Arm II, sunitinib alone; or Arm III, the com-
bination of pemetrexed and sunitinib, with a primary end point 
of improvement in 18-week progression-free survival (PFS).
Sunitinib is a small-molecule inhibitor of multiple 
receptor tyrosine kinases, including VEGFR, platelet-derived 
growth factor receptor (PDGFR), FGFR1, cKIT, FLT3, and 
RET kinases.5 Sunitinib as monotherapy in patients with 
advanced NSCLC has been tested in multiple studies.6–8 
Among previously treated NSCLC patients, at 50 mg/day on 
a 4-week on and 2-week off schedule, overall response rate 
(RR) was 11.1% with median PFS of 12 weeks and median 
OS of 23.4 weeks.8 Subsequent studies in NSCLC showed 
that continuous daily dosing at 37.5 mg/day resulted in similar 
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median PFS of 11.9 weeks and median OS of 37.1 weeks.7 
On the basis of these phase 2 data, sunitinib was a rational 
choice to test in the second-line setting, either as monotherapy 
or combined with second-line chemotherapy. Combination of 
sunitinib, at either 37.5 mg/day continuous dosing or 50 mg/
day on a 2-week on and 1-week off schedule, with pemetrexed 
at 500 mg/m2 on day 1 of every 21 days, has been found to be 
well tolerated in the phase 1 setting.9
PATIENTS AND METHODS
Patients
Patients aged 18 years or older with histologically or 
cytologically proven advanced NSCLC (stage IIIB or IV) with 
evidence of progression after first-line therapy were eligible. 
Prior bevacizumab was allowed. There were no restrictions 
regarding histologic subtype of NSCLC, and central review 
was not required. Patients were required to have Eastern 
Cooperative Oncology Group performance status (PS) of 0 or 
1 and adequate hematologic, liver, and kidney function defined 
by laboratory testing. Treated, asymptomatic brain metastases 
were allowed. Exclusion criteria included: symptomatic con-
gestive heart failure, active coronary artery disease defined as 
myocardial infarction or unstable angina in the past year, cere-
brovascular accident or transient ischemic accident in the past 
year, uncontrolled hypertension, hemoptysis, cavitary pulmo-
nary lesions, history of thromboembolism, or requirement for 
full-dose therapeutic anticoagulation.
Study Design and Treatment
This was a randomized, open-label phase 2 study with 
patients randomized in a 1:1:1 allocation to one of three arms: 
Arm I, pemetrexed alone at 500 mg/m2 on day 1; Arm II, suni-
tinib alone at 37.5 mg/day; and Arm III, pemetrexed 500 mg/m2  
on day 1 with sunitinib 37.5 mg daily. One cycle was consid-
ered 21 days. Randomization was stratified by PS (0/1), stage 
(IIIB/IV), and sex (male/female) using a stratified permuted 
block-randomization scheme.
The primary objective of the study was to estimate the 
18-week PFS survival rate in each of the three arms of the 
study. Secondary objectives included: RRs, PFS, OS, and tox-
icity in the three arms.
The study was planned to randomize a total 225 eligible 
patients. With 75 patients in each arm, the study has at least 
80% power to detect a 18-week PFS rate of 56.3% for either 
experimental arm (Arm II or III) versus the expected 18-week 
PFS rate of 37.1% for the control arm (Arm I) with each com-
parison performed at the one-sided 0.10 significance level.
The study was activated on April 15, 2008, and closed 
on September 15, 2011, after 130 patients had been regis-
tered. Each participant signed an Institutional Review Board–
approved, protocol-specific informed consent in accordance 
with federal and institutional guidelines. The study was termi-
nated early because of slow accrual and changing paradigms 
of therapy in metastatic NSCLC, specifically, the increased 
use of first-line or maintenance pemetrexed and the restriction 
of pemetrexed use to patients with nonsquamous histologies. 
The 130 registered patients were considered eligible and were 
randomized. Of them, five patients withdrew after randomiza-
tion and did not receive protocol treatment. All 130 patients 
who were registered and randomized were included in the 
final  intention-to-treat analysis conducted in June 2013. Of 
note, analyses were also done excluding the five patients who 
did not receive protocol treatment, and the results were similar 
to those reported here. Data collection and statistical analy-
ses were conducted by the Alliance Statistics and Data Center. 
Data quality was ensured by review of data by the Alliance 
Statistics and Data Center and by the study chairperson fol-
lowing Alliance policies.
Assessments
Computed tomography scans of the chest and upper 
abdomen were obtained at baseline and at 6-week inter-
vals. Radiographic review was done locally and Response 
Evaluation Criteria in Solid Tumors version 1.0 criteria were 
used to define response and progression. Specifically, pro-
gression was defined as at least a 20% increase in the sum 
of the longest diameter (LD) of target lesions, taking as ref-
erences the smallest sum LD recorded since the treatment 
started, or the appearance of one or more new lesions. PFS 
was defined as the time from registration to disease progres-
sion or death from any cause, whichever came first. OS was 
defined as the time from registration to death of any cause. 
Adverse events were assessed and graded using National 
Cancer Institute Common Toxicity Criteria version 4.0. For 
additional safety monitoring, the initial cohort of 12 patients 
in the two experimental arms (Arms II and III) were followed 
for adverse events during the first cycle of therapy, with a 
stopping rule that if more than  one-third of the initial patient 
cohort experienced a dose-limiting toxicity, then patient 
accrual would be stopped for the study team to review the 
cumulative safety data and make recommendations regard-
ing changing the dose level or terminating the trial.
Statistical Analysis
The balance of baseline covariates between the treat-
ment arms, including age, sex, race, histology, stage, PS, 
prior radiotherapy, prior surgery, and number of prior che-
motherapy regimens (1, 2+), was tested using χ2 exact 
tests. The Kaplan–Meier product limit estimator10 was used 
to graphically describe OS and PFS. Median survival and 
18-week survival rates by treatment arm, with 95% confi-
dence intervals (CIs), were derived from the product limit 
estimates. Comparisons of PFS and OS were conducted 
using a log-rank test. The Cox proportional hazards model 
was used to estimate the hazard ratios and their 95% CIs 
of the experimental regimens relative to the control arm, 
with and without adjusting for baseline prognostic factors 
and their interactions with treatments. Backward selection 
was used for selecting significant baseline covariates and 
the interactions. The proportion of patients who responded 
(completely or partially) to each treatment regimen was esti-
mated as well as their associated 95% CIs. Differences in 
RR (complete and partial response) were evaluated using 
the Cochran–Mantel–Haenszel test and using a multivari-
ate logistic regression model. The type and grade of toxicity 
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associated with each treatment regimen were summarized. 
The planned one-sided test on 18-week PFS between the 
arms was conducted and is reported in this article. However, 
because the outcome is contrary to the hypothesized direc-
tion, we also report the two-sided p value for this test, as 
two-sided p values are not dependent on the direction of 
hypothesized effects and are more appropriate for descriptive 
purposes. For all other statistical tests, two-sided p values 
were reported, and because of the small size of the final 
accruals, these p values are considered purely descriptive.
RESULTS
Patients and Treatment Exposure
Between April 2008 and September 2011, 130 patients 
were registered: 42 in Arm I (pemetrexed alone), 47 in Arm II 
(sunitinib alone), and 41 in Arm III (pemetrexed + sunitinib). 
Median follow-up time was 36 months. Five patients did not 
receive protocol treatment after randomization (Fig. 1). Table 1 
shows the clinical and demographic characteristics of the 130 
patients. Baseline characteristics in the three arms were well 
FIGURE 1.  CONSORT diagram. AST, aspartate transaminase, BP, blood pressure. 
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balanced (all p > 0.10). The median age was 63 years, with a 
range from 38 to 84. Fifty-three percent were male; 12% had 
stage IIIB disease and 88% stage IV. There were no significant 
differences between the treatment arms in age, sex, stage, PS, 
or number of prior chemotherapy regimens. Histologic diag-
nosis was predominantly adenocarcinoma (64% overall), with 
13% squamous histology and no significant differences in his-
tology distribution between the three arms.
Efficacy
Table 2 summarizes the best overall response. There 
were no complete responses. The rates of partial response and 
stable disease in the three arms were: pemetrexed (14% par-
tial response [PR]/50% stable disease [SD]), sunitinib (17% 
PR/38% SD), pemetrexed + sunitinib (22% PR/51% SD). 
Despite a numerically higher PR rate in the combination arm, 
these differences were not statistically significant (p = 0.34).
More importantly, these PR rates did not translate 
to advantages in either PFS or OS for the combination arm 
(Table 3). The 18-week PFS rate in the three arms was not 
significantly different (2-df Wald test, one-sided p = 0.88 and 
two-sided p = 0.25), with an 18-week PFS rate in the peme-
trexed arm of 54% (95% CI, 40–71), sunitinib 37% (95% CI, 
25–54), and pemetrexed + sunitinib 48% (95% CI, 35–66). 
Median PFS was 4.9 months (95% CI, 2.1–8.8) for peme-
trexed alone, 3.3 months (95% CI, 2.3–4.2) for sunitinib alone, 
and 3.7 months (95% CI, 2.5–5.8) for pemetrexed + sunitinib 
(p = 0.18; Fig. 2A). The hazard ratio for sunitinib alone over 
pemetrexed alone is 1.4 (95% CI, 0.9–2.2) and that for peme-
trexed + sunitinib over pemetrexed is 1.3 (95% CI, 0.9–2.1), 
estimated from a multivariate Cox model with adjustment for 
significant baseline covariates.
OS was significantly better with pemetrexed alone. 
Median OS was 10.5 months (95% CI, 8.3–20.2) for peme-
trexed alone, 8.0 months (95% CI, 6.8–13.5) for sunitinib 
alone, and 6.7 months (95% CI, 4.1–10.1) for pemetrexed + 
sunitinib (p = 0.03; Fig. 2B). The hazard ratio for sunitinib 
alone over pemetrexed alone is 1.4 (95% CI, 0.9–2.3) and 
that for pemetrexed + sunitinib over pemetrexed is 2.0 (95% 
CI, 1.2–3.2), estimated from a multivariate Cox model with 
adjustment for significant baseline covariates.
Analysis of the squamous subset is exploratory only 
as there were only 17 squamous patients on study (Table 4). 
There was no benefit in PFS or OS to the sunitinib or peme-
trexed + sunitinib arms in either the squamous or nonsqua-
mous subsets. The OS benefit seen with pemetrexed alone was 
seen only in the nonsquamous arm.
Safety
Table 5 shows the rates of grade 3 to 5 toxicities in the three 
arms. Overall, toxicity was higher in the  sunitinib-containing 
arms compared with pemetrexed alone. There was signifi-
cantly more fatigue in the  sunitinib-containing arms, as well 
as more gastrointestinal side effects. Cardiovascular events 
and thrombotic/hemorrhagic events also clustered more in the 
sunitinib-containing arms although the absolute numbers of 
these were small. Of the five grade 5 events, two (hemoptysis 
in the sunitinib arm and pneumonia in setting of neutropenia 
in pemetrexed + sunitinib arm) were thought to be treatment 
related, and one (pulmonary embolus in pemetrexed + suni-
tinib arm) was thought probably treatment related. The grade 5 
hemoptysis death occurred in a patient with adenocarcinoma.
Because there were only 17 squamous patients on study, 
a comparison of toxicity between squamous and nonsqua-
mous is limited by small sample size. However there was no 
obvious signal for increased toxicity in the squamous patients.
TABLE 1.  Patient Characteristics
Characteristic
Arm I
n = 42
Arm II
n = 47
Arm III
n = 41
Total
N = 130
Age, median: 63; range (38–84)
  <60 16 (38%) 15 (32%) 15 (37%) 46 (35%)
  60–70 15 (36%) 24 (51%) 13 (32%) 52 (40%)
  ≥70 11 (26%) 8 (17%) 13 (32%) 32 (25%)
Sex
  Male 22 (52%) 25 (53%) 22 (54%) 69 (53%)
  Female 20 (48%) 22 (47%) 19 (46%) 61 (47%)
Race
  White 36 (86%) 43 (91%) 32 (78%) 111 (85%)
  Black 5 (12%) 3 (6%) 8 (20%) 16 (12%)
  Asian 0 (0%) 1 (2%) 1 (2%) 2 (1%)
  More than one race 1 (2%) 0 (0%) 0 (0%) 1 (1%)
Ethnicity
  Non-Hispanic 39 (93%) 47 (100%) 36 (88%) 122 (94%)
  Hispanic 2 (5%) 0 (0%) 1 (2%) 3 (2%)
  Unknown 1 (2%) 0 (0%) 4 (10%) 5 (4%)
Histology
  Adenocarcinoma 28 (67%) 28 (60%) 27 (66%) 83 (64%)
  Squamous cell 4 (10%) 7 (15%) 6 (15%) 17 (13%)
  Large cell 2 (5%) 4 (9%) 0 (0%) 6 (5%)
  Undifferentiated NSC 3 (7%) 6 (13%) 1 (2%) 10 (8%)
  Other 3 (7%) 2 (4%) 7 (17%) 12 (9%)
  Missing 2 (5%) 0 (0%) 0 (0%) 2 (2%)
Stage
  IIIB 5 (12%) 8 (17%) 3 (7%) 16 (12%)
  IV 37 (88%) 39 (83%) 38 (93%) 114 (88%)
Prior surgery
  No 24 (57%) 34 (72%) 30 (73%) 88 (68%)
  Yes 16 (38%) 12 (26%) 11 (27%) 39 (30%)
  Missing 2 (5%) 1 (2%) 0 (0%) 3 (2%)
Prior XRT
  No 22 (52%) 26 (55%) 21 (51%) 69 (53%)
  Yes 17 (40%) 21 (45%) 20 (49%) 58 (45%)
  Missing 3 (7%) 0 (0%) 0 (0%) 3 (2%)
No. of prior chemo regimens
  1 38 (90%) 43 (91%) 39 (95%) 120 (92%)
  2+ 1 (2%) 4 (9%) 0 (0%) 5 (4%)
  Missing 3 (7%) 0 (0%) 2 (5%) 5 (4%)
Performance status
  0 13 (31%) 17 (36%) 14 (34%) 44 (34%)
  1 29 (69%) 30 (64%) 27 (66%) 86 (66%)
NSC, non-small cell lung cancer; XRT, radiation. 
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TABLE 2.  Best Overall Response
Best Response
Arm I
n = 42
Arm II
n = 47
Arm III
n = 41
Total
N = 130
Partial response 6 (14%) 8 (17%) 9 (22%) 23 (18%)
Stable 21 (50%) 18 (38%) 21 (51%) 60 (46%)
Progression 13 (31%) 13 (28%) 6 (15%) 32 (25%)
Missing or unevaluable 2 (5%) 8 (17%) 5 (12%) 15 (12%)
Response rate (95% CI)a 14 (5%–29%) 17 (8%–31%) 22 (11%–38%) 18 (12%–25%)
aThe 95% CI was exact confidence intervals.
bThe Cochran–Mantel–Haenszel test p value is 0.363 for testing response (CR + PR) homogeneity across three treatment arms.
CR, complete response; PR, partial response.
TABLE 3.  Eighteen-Week PFS and Median PFS and OS (95% CI) by Treatment Arm
Arm I
n = 42
Arm II
n = 47
Arm III
n = 41
Two-df Wald or  
Log-Rank Test
Total
N = 130
Eighteen-week PFS rate 53.7 (40.4–71.3) 37.0 (25.4–53.9) 48.1 (34.9–66.3) 0.252 45.9 (38.0–55.4)
Median PFS (mo) 4.9 (2.1–8.8) 3.3 (2.3–4.2) 3.7 (2.5–5.8) 0.191 3.6 (2.8–4.4)
Median OS (mo) 10.5 (8.3–20.2) 8.0 (6.8–13.5) 6.7 (4.1–10.1) 0.019 8.3 (7.3–10.4)
PFS, progression-free survival; OS, overall survival; CI, confidence interval.
FIGURE 2. A, Progression-free survival. B, Overall survival.
TABLE 4.  PFS and OS by Squamous and Nonsquamous Histology
Median Survival (95% CI) (mo) Two-df Log-Rank Test
Arm I (Pem) Arm II (Sun) Arm III (Pem + Sun) p
Squamous N = 4 N = 7 N = 6
  PFS 2.02 (1.22–7.85) 4.10 (1.35–5.52) 1.77 (0.39–7.20) 0.650
  OS 9.28 (7.85–.) 10.18 (6.80–15.54) 4.70 (0.39–14.72) 0.259
Nonsquamous N = 38 N = 40 N = 35
  PFS 5.13 (1.71–9.49) 2.96 (1.68–4.17) 4.17 (2.53–5.78) 0.210
  OS 13.04 (8.25–17.45) 7.29 (4.83–13.47) 7.13 (3.68–9.89) 0.089
PFS, progression-free survival; OS, overall survival; CI, confidence interval.
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DISCUSSION
In this randomized phase 2 study, we investigated the 
role of sunitinib in the second-line setting in NSCLC by treat-
ing patients with either pemetrexed alone, sunitinib alone, or 
the combination of pemetrexed and sunitinib. The primary 
end point, 18-week PFS rate, was not significantly different 
between the three arms. However, there was a trend toward 
improved PFS with pemetrexed alone, and OS was signifi-
cantly better with pemetrexed alone. In addition, we found 
that pemetrexed had a superior safety profile to either suni-
tinib or the combination of pemetrexed and sunitinib.
This study was closed prematurely because of slowing 
accrual rates. The slow accrual was thought to be a result of 
global changes in management in NSCLC, specifically the 
increased adoption of maintenance chemotherapy as well 
as the increasing limitation of pemetrexed to nonsquamous 
histology only. Therefore, the study as completed is not ade-
quately powered to address the primary end point of differ-
ence in 18-week PFS rate. Despite this, the study suggests that 
pemetrexed remains the best treatment option in this setting 
and the single-agent activity of sunitinib or the addition of 
sunitinib to pemetrexed yielded no benefit. This validates our 
approach of carefully exploring treatment options in a phase 
2 setting before committing to phase 3 trials and reconfirms 
the very limited role of antiangiogenic drugs thus far in lung 
cancer.
It is not entirely clear why the OS was superior in the 
pemetrexed alone arm. Of note, there were significantly fewer 
patients in the pemetrexed plus sunitinib arm who subse-
quently went on to receive further lines of therapy (54% in 
pemetrexed alone arm received subsequent chemotherapies, 
63% in sunitinib arm, and 22% in pemetrexed plus sunitinib 
arm). Within each treatment arm, patients who received sub-
sequent therapies had significantly longer survival than those 
without. Whether the relative lack of subsequent therapies in 
the combination arm is simply a reflection of the worse out-
comes seen in that arm, or possibly contributed to that worse 
survival, is unknown. Although similar percentages of patients 
in the sunitinib only and pemetrexed only arms went on to 
receive further therapies, the median PFS in the sunitinib arm 
is the shortest of the three treatment regimens and it is pos-
sible that the limited activity of sunitinib in the second-line 
setting contributed to the shorter OS in that arm relative to the 
pemetrexed only arm.
Other trials combining VEGFR tyrosine kinase inhibi-
tors with chemotherapy have yet to show a benefit to the com-
bination. Many of these studies demonstrate higher rates of 
adverse events with combination therapy. A phase 3 study in 
TABLE 5.  Treatment-Related ≥Grade 3 Adverse Events
Arm I Arm II Arm III
Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5
Overall AEs 9 (22%) 3 (7%) 0 24 (55%) 3 (7%) 2 (5%) 18 (46%) 10 (26%) 3 (8%)
Hematologic AEs 6 (15%) 1 (2%) 0 8 (18%) 2 (5%) 0 8 (21%) 10 (26%) 0
Low hemoglobin 1 (2%) 0 0 3 (7%) 0 0 3 (8%) 0 0
Low ANC 2 (5%) 0 0 2 (5%) 1 (2%) 0 3 (7%) 8 (21%) 0
Low platelets 1 (2%) 1 (2%) 0 2 (5%) 1 (2%) 0 6 (15%) 2 (5%) 0
Febrile neutropenia 0 (0%) 0 0 0 0 0 1 (3%) 0 0
Nonhematologic AEs 5 (12%) 3 (7%) 0 23 (52%) 1 (2%) 2 (5%) 20 (51%) 1 (3%) 3 (8%)
Constitutional
  Fatigue 3 (7%) 1 (2%) 0 12 (27%) 0 0 9 (23%) 0 0
  Infection 1 (2%) 0 0 2 (4%) 0 0 0 0 2 (6%)
Gastrointestinal
  Nausea 0 0 0 1 (2%) 0 0 3 (8%) 0 0
  Vomiting 0 0 0 0 0 0 2 (5%) 0 0
  Mucositis 0 0 0 1 (2%) 0 0 3 (8%) 0 0
  Diarrhea 1 (2%) 0 0 0 0 0 0 0 0
  Elevated ALT 0 0 0 1 (2%) 0 0 1 (3%) 0 0
  Elevated AST 1 (2%) 0 0 2 (5%) 0 0 0 0 0
Dermatologic
  Rash (hand-foot) 0 0 0 3 (7%) 0 0 0 0 0
Cardiovascular
  Cardiac ischemia 0 0 0 0 0 1 (2%) 0 0 0
  Hypertension 1 (2%) 0 0 2 (5%) 0 0 2 (5%) 0 0
  Pulmonary hemorrhage 0 0 0 0 0 1 (2%) 0 0 0
  Other hemorrhage 0 0 0 0 0 0 1 (3%) 0 0
  Thrombosis/embolism 0 0 0 0 0 0 1 (3%) 0 1 (3%)
ANC, absolute neutrophil count; ALT, alanine aminotransferase; AST, aspartate transaminase; AEs, adverse events. 
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the first-line setting of carboplatin and paclitaxel with or with-
out sorafenib was terminated early when interim analysis con-
cluded that the study was highly unlikely to meet its primary 
end point of OS benefit. Of note, patients with squamous his-
tology had greater mortality in the combination arm.11 BR24, 
a large randomized phase 2/3 study in first-line NSCLC of car-
boplatin and paclitaxel with cediranib or placebo, was halted 
after the phase 2 portion as rates of serious adverse events 
were significantly higher in the cediranib arm.12 However, 
because of signals of potential clinical benefit, with a statisti-
cally significant higher RR and trend toward better PFS in the 
cediranib arm, plans to proceed at a 20 mg dose of cediranib 
in the phase 3 setting are underway. In the previously treated 
setting, the combination of sunitinib with erlotinib did not 
improve OS over erlotinib alone, despite statistically signifi-
cant improvements in RR and PFS.13 Again, treatment-related 
adverse events were higher with the combination.
Similar to these studies, we found a higher rate of 
adverse events in the sunitinib-containing arms. Although we 
did not have a large proportion of squamous patients on the 
current study, there was no signal that the squamous patients 
in particular did any worse in terms of toxicity than the non-
squamous patients. Whether the relatively less toxicity seen 
with pemetrexed alone was another factor in the improved OS 
is also a possibility. Overall grade 3 to 4 toxicity was higher in 
this study in the sunitinib-containing arms as compared with 
the pemetrexed alone arm. Differences in these side effects 
can be quite clinically significant for patients, particularly as 
significant fatigue or gastrointestinal side effects may impact 
patients’ PS, ability to tolerate current therapies, and fitness 
and tolerance for future therapies.
Whether a subset of patients exists who would derive 
benefit from sunitinib remains an open question. As a multi-
targeted agent, sunitinib inhibits multiple kinases other than 
the VEGFR and is not solely an antiangiogenic agent. In par-
ticular, the inhibitory activity against RET and PDGFR are 
of interest. Recently, RET kinase fusions have been identified 
as a novel potential oncogenic driver in lung cancer.14–17 The 
most common fusion partner in lung cancer is KIF5B although 
CCDC6-RET fusions have been reported as well. The fusion 
gene causes overexpression of the RET receptor tyrosine 
kinase and occurs in approximately 1% to 2% of lung adeno-
carcinomas. Cell lines engineered to harbor the RET fusion 
have been shown to be transforming, and sensitive to several 
multitargeted kinase inhibitors that inhibit RET, including 
sunitinib, sorafenib, and vandetanib. Another potential bio-
marker for sunitinib response may be PDGFRA amplification. 
High throughput cell line screening revealed that two of 637 
cell lines had significant sensitivity to single-agent sunitinib.18 
Both of these cell lines (one NSCLC and one rhabdomyosar-
coma) showed PDGFRA activation with high levels of expres-
sion of phosphorylated PDGFRA, with focal PDGFRA gene 
amplification seen in the NSCLC cell line.
Although these data from cell lines for RET fusion and 
PDGFRA amplification are suggestive, there are as yet no 
clinical data that such molecular changes in patients confer 
sensitivity to sunitinib. This trial did not mandate tumor col-
lection from patients and the small sample size would make 
the likelihood of finding any specific genetic alteration quite 
low. However, future studies investigating this question would 
be of interest to determine whether specific molecularly 
defined subsets of patients may benefit from sunitinib.
This study has several limitations that should temper 
any interpretation of these results. We were able to accrue only 
a little over half the goal accrual for this study. The limited 
sample size severely limits our ability to draw definitive con-
clusions from this data. Variation between the arms may be 
a function of small numbers. Ultimately, however, this study 
does not support the use of sunitinib in the second-line setting 
in NSCLC.
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